Search results for "Marker"

showing 10 items of 3799 documents

Caveolin-1, breast cancer and ionizing radiation

2015

Breast cancer (BC) recovery has increased in recent years thanks to efforts of Omics-based research in this field. However, despite the important results obtained, BC remains a complex multifactorial pathology that is difficult to treat appropriately. Caveolin-1 (CAV1), the basic constituent protein of specialized plasma membrane invaginations called caveolae, is emerging as a potential therapeutic biomarker in BC. This factor may modulate BC response to chemotherapy and radiation therapy. In addition, recent reports describe the key role of CAV1 during cell response to oxidative stress. The aim of the present review was to describe the biological roles of CAV1 in BC considering its contras…

RadiotherapyAnimalCAV1; biomarker; breast cancer; ionizing radiation; review; Animals; Biomarkers Tumor; Breast Neoplasms; Caveolin 1; Cell Transformation Neoplastic; Female; Gene Expression Regulation Neoplastic; Humans; Molecular Targeted Therapy; Radiotherapy; Receptor Epidermal Growth Factor; Radiation IonizingCaveolin 1reviewBreast NeoplasmsErbB ReceptorsGene Expression Regulation Neoplasticbreast cancerCell Transformation NeoplasticCAV1Radiation IonizingBiomarkers TumorAnimalsHumansbiomarkerFemaleMolecular Targeted TherapyReceptor Epidermal Growth Factorionizing radiationBreast NeoplasmHuman
researchProduct

Using mRNA and small RNA gene expression changes in peripheral blood for easy detection of Ra-223 incorporation

2019

Radium-223Small RNARadiation analysisEnvironmental EngineeringmRNAlcsh:QR1-502Biologylcsh:Microbiologylcsh:PhysiologyIndustrial and Manufacturing EngineeringTranscriptomeProstate cancerRadium-223lcsh:ZoologyGene expressionmedicineradiation biomarkerssmall RNAincorporationlcsh:QL1-991Messenger RNAlcsh:QP1-981gene expression changesprostate cancermedicine.diseaseMolecular biologyPeripheral bloodtranscriptomemedicine.drugBIO Web of Conferences
researchProduct

Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors

2008

To review the implication of CXCR4 for gastrointestinal cancer, a "Pubmed" analysis was performed in order to evaluate the relevance of CXCR4 and its ligands for gastrointestinal cancers. Search terms applied were "cancer, malignoma, esophageal, gastric, colon, colorectal, hepatic, pancreatic, CXCR4, SDF-1alpha, and SDF-1beta". CXCR4 expression correlated with dissemination of diverse gastrointestinal malignomas. The CXCR4 ligand SDF-1alpha might act as "chemorepellent" while SDF-1beta might act as "chemorepellent" for CTLs, inducing tumor rejection. The paracrine expression of SDF-1alpha was furthermore closely associated with neoangiogenesis. CXCR4 and its ligands influence the disseminat…

Receptors CXCR4Prognostic factorGastrointestinal tumorsBiologyLigandsCXCR4Paracrine signallingChemokine receptorBiomarkers TumormedicineAnimalsHumansNeoplasm InvasivenessGastrointestinal cancerNeoplasm MetastasisGastrointestinal NeoplasmsGastroenterologyCancerGeneral Medicinemedicine.diseaseChemokine CXCL12EditorialTreatment OutcomeSearch termsImmunologyCancer researchWorld Journal of Gastroenterology
researchProduct

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

2009

Abstract Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast cancer subtypes, 28 MBCs were compared with common breast cancers using comparative genomic hybridization, transcriptional profiling, and reverse-phase protein arrays and by sequencing for common breast cancer mutations. MBCs showed unique DNA copy number aberrations compared with common breast cancers. PIK3CA mutations were detected in 9 of 19 MBCs (47.4%) versus 80 of 232 hormone receptor–positive cancers (34.5%; P = 0.32), 17 of 75 HER-2–positive samples (22.7%; P = 0.04), 20 of 240 basal-like c…

Receptors SteroidCancer ResearchPathologymedicine.medical_specialtyTranscription GeneticClass I Phosphatidylinositol 3-KinasesBreast NeoplasmsArticleCohort StudiesProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesBreast cancerProto-Oncogene ProteinsBiomarkers TumormedicineHumansRNA NeoplasmEpithelial–mesenchymal transitionskin and connective tissue diseasesComparative Genomic HybridizationMetaplasiabiologyGene Expression ProfilingCD44PTEN PhosphohydrolaseCancerEpithelial CellsMesenchymal Stem CellsSarcomaDNA NeoplasmMetaplastic Breast Carcinomamedicine.diseaseClaudin-LowOncologyMutationCarcinoma Squamous Cellras Proteinsbiology.proteinCancer researchFemaleBreast diseaseStem cellProto-Oncogene Proteins c-aktCancer Research
researchProduct

Prepulse inhibition can predict the motivational effects of cocaine in female mice exposed to maternal separation

2020

The prepulse inhibition (PPI) of the startle response can identify the rodents that are more sensitive to the effects of cocaine. Mice with a lower PPI presented a higher vulnerability to the effects of cocaine and a higher susceptibility to developing a substance use disorder (SUD). Maternal separation with early weaning (MSEW) is a relevant animal model to induce motivational alterations throughout life. Nevertheless, only a few studies on females exist, even though they are more vulnerable to stress- and cocaine-related problems. Hence, the aim of the present study was to evaluate the ability of PPI to identify females with a greater vulnerability to the long-term consequences of early s…

Reflex StartleStartle responseAnhedoniaPhysiologySelf AdministrationWeaningReinforcing effectsMiceBehavioral NeuroscienceAnimal modelCocaineDopamine Uptake InhibitorsMaternal separation with early weaningFemale micemedicineAnimalsPrepulse inhibitionMotivationmedicine.diagnostic_testPrepulse Inhibitionbusiness.industryMaternal Deprivationmedicine.diseaseAnhedonia-like behavioursConditioned place preferenceSubstance abuseDisease Models AnimalLocomotor sensitizationConditioning OperantBiomarker (medicine)FemalePassive avoidancebusinessBehavioural Brain Research
researchProduct

Role of non-coding RNAs as biomarkers of deleterious cardiovascular effects in sepsis.

2021

The mechanisms occurring during sepsis that produce an increased risk of cardiovascular (CV) disease (CVD) are poorly understood. Even less information exists regarding CV dysfunction as a complication of sepsis, particularly for sepsis-induced cardiomyopathy. However, recent research has demonstrated that non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, play a crucial role in genetic reprogramming, gene regulation, and inflammation during the development of CVD. Here we describe experimental findings showing the importance of non-coding RNAs mediating relevant mechanisms underlying CV dysfunction after sepsis, so contributing to sepsis-induced cardiomyopathy. …

Regulation of gene expressionbusiness.industryCardiomyopathyInflammationDiseaseRNA Circularmedicine.diseaseBioinformaticsRisk AssessmentSepsisMicroRNAsHeart Disease Risk FactorsSepsismicroRNAmedicineAnimalsHumansRNA Long NoncodingEpigeneticsmedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiomyopathiesReprogrammingBiomarkersProgress in cardiovascular diseases
researchProduct

Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium

2016

AIMS: Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively.METHODS AND RESULTS: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin …

Relative risk reductionPathologymedicine.medical_specialtyBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAPopulationBiomarker For Cardiovascular Risk Assessment In Europe ; Cardiovascular Risk ; High-sensitivity Assayed Troponin I ; Monica Risk Genetics Archiving And Monograph ; Mortality030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInternal medicineTroponin IMedicineRosuvastatin030212 general & internal medicineMortalityeducationBiomarker for Cardiovascular Risk Assessment in Europe; Cardiovascular risk; High-sensitivity assayed troponin I; MONICA Risk Genetics Archiving and Monograph; Mortalityeducation.field_of_studyFramingham Risk Scorebiologybusiness.industryHazard ratioAbsolute risk reductionBiomarker for Cardiovascular Risk Assessment in EuropeCardiovascular riskMONICA Risk Genetics Archiving and MonographTroponinHigh-sensitivity assayed troponin I3. Good healthCardiologybiology.protein/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct

Proliferative activity in stenotic human aortocoronary bypass grafts

2002

Abstract Background: Aortocoronary bypass graft disease is responsible for long-term failure of autologous vein grafts. The analyses of proliferation and cell type characterisation in human bypass grafts harvested during re-do surgery make it possible to investigate the cellular processes leading to bypass graft failure. Methods: 30 stenotic vein grafts and 25 control veins were explantated during re-do heart surgery procedures. The total area and cell count of the neointima, media and adventitia were calculated computer-assisted. Actively proliferating cells were identified using antibody to Ki-67 and positive cells were determined by double-label immunocytochemistry with SMC α-actin, CD 3…

ReoperationNeointimaCell typemedicine.medical_specialtyPathologyProliferation indexT-LymphocytesImmunocytochemistryCellCell CountBypass graftsMuscle Smooth VascularPathology and Forensic MedicineAntigens CDAdventitiaInternal medicineHumansMedicineSaphenous VeinCoronary Artery Bypassbiologybusiness.industryMacrophagesGraft SurvivalGraft Occlusion VascularGeneral MedicineImmunohistochemistryActinsKi-67 Antigenmedicine.anatomical_structurecardiovascular systembiology.proteinCardiologyAntibodyCardiology and Cardiovascular MedicinebusinessBiomarkersCell DivisionCardiovascular Pathology
researchProduct

Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring

2022

Ki-67 assessment is a key step in the diagnosis of neuroendocrine neoplasms (NENs) from all anatomic locations. Several challenges exist related to quantifying the Ki-67 proliferation index due to lack of method standardization and inter-reader variability. The application of digital pathology coupled with machine learning has been shown to be highly accurate and reproducible for the evaluation of Ki-67 in NENs. We systematically reviewed all published studies on the subject of Ki-67 assessment in pancreatic NENs (PanNENs) employing digital image analysis (DIA). The most common advantages of DIA were improvement in the standardization and reliability of Ki-67 evaluation, as well as its spee…

Reproducibility of ResultsBreast NeoplasmsCarcinoid TumorPathology and Forensic MedicinePancreatic Neoplasmsneuroendocrine neoplasms pancreasNeuroendocrine TumorsKi-67 AntigenGastroenteropancreatic Neuroendocrine TumorBiomarkers TumorImage Processing Computer-AssistedHumansGastroenteropancreatic Neuroendocrine Tumor; Cancer; Carcinoid TumorFemaleCell ProliferationCancer
researchProduct

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

2015

While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in …

Research designPathologyData baseResearch methodologyElectronic medical recordDiseaseReviewProceduresTreatment responseClinical trials; Rare cancers; Research methodology; Clinical Studies as Topic; Humans; Neoplasms; Rare Diseases; Research Design; Hematology; OncologyClinical trialsNeoplasmsReimbursementPriority journaleducation.field_of_studyClinical Studies as TopicClinical studies as topicHematologyRare diseasesEuropeOncologyResearch designResearch DesignClinical decision makingHumanmedicine.medical_specialtyPractice guidelineCase findingPopulationHealth care qualityReviewsCancer researchClinical studyRare DiseasesSDG 3 - Good Health and Well-beingConceptual frameworkmedicineHumansRare cancersTumor markerIntensive care medicineeducationAntineoplastic activityFlexibility (engineering)Surrogate endpointbusiness.industryMethodologyRare cancerStudy designCancer survivalReimbursementClinical trialClinical trials; Rare cancers; Research methodology; Hematology; OncologyPatient informationClinical effectivenessPosition paperNeoplasmbusinessRare disease
researchProduct